Literature DB >> 23711509

Regional regulation of glutamate signaling during cuprizone-induced demyelination in the brain.

Abolfazl Azami Tameh1, Tim Clarner, Cordian Beyer, Mohammad Ali Atlasi, Gholamreza Hassanzadeh, Homayoun Naderian.   

Abstract

Glutamate excitotoxicity is associated with a wide range of neurodegenerative disorders and also seems to be involved in the pathology of demyelinating disorders such as multiple sclerosis (MS). Cuprizone-induced toxic demyelination shows clear characteristics of MS such as demyelination and axonal damage without the involvement of the innate immune system. In this study, we have evaluated glutamate signaling during cuprizone-induced demyelination in the white and gray matter of mouse brain by studying the expression of ionotropic and metabotropic glutamate-receptors and -transporters by Affymetrix gene array analysis, followed by real-time PCR and western blot analysis. Cellular localization of glutamate transporters was investigated by fluorescence double-labeling experiments. Comparing white and gray matter areas, the expression of glutamate receptors was region-specific. Among NMDA receptor subunits, NR2A was up-regulated in the demyelinated corpus callosum (CC), whereas the metabotropic glutamate receptor mGluR2 was down-regulated in demyelinated gray matter. Glutamate-aspartate transporter (GLAST) co-localizing with GFAP(+) astrocytes was increased in both demyelinated CC and telencephalic cortex, whereas Slc1a4 transporter was up-regulated only in CC. Our data indicate that cuprizone treatment affects glutamate-receptors and -transporters differently in gray and white matter brain areas revealing particularly regulation of GLAST and Slc1a4 compared with other genes. This might have an important influence on brain-region selective sensitivity to neurotoxic compounds and the progression of demyelination as has been reported for MS and other demyelinating neurological diseases.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  AMPA; BSA; CC; CNS; Cuprizone; Demyelination; EAAT; EAE; ECL; GFAP; GLAST; GLT; Glutamate receptor; Glutamate transporter; Gria; Grm; HPRT; HRP; IHC; Iba; MAPK; MBP; MGluRs; MOG; MS; N-methyl-d-aspartate; NMDA; NO; PBS; PLP; PVDF; SDS; SLC; TGF-β1; bovine serum albumin; central nervous system; corpus callosum; enhanced chemiluminescence; excitatory amino acid transporter; experimental allergic encephalomyelitis; glial fibrillary acidic protein; glutamate receptor, ionotropic AMPA; glutamate receptor, metabotropic; glutamate transporter; glutamate–aspartate transporter; horseradish peroxidase; hypoxanthine-guanine phosphoribosyltransferase; immunohistochemistry; ionized calcium-binding adaptor molecule; metabotropic glutamate receptors; mitogen-activated protein kinase; multiple sclerosis; myelin basic protein; myelin oligodendrocyte glycoprotein; nitric oxide; phosphate-buffered saline; polyvinylidenfluoride; proteolipid protein; sodium dodecylsulfate; solute carrier; transforming growth factor-beta 1; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

Mesh:

Substances:

Year:  2013        PMID: 23711509     DOI: 10.1016/j.aanat.2013.03.004

Source DB:  PubMed          Journal:  Ann Anat        ISSN: 0940-9602            Impact factor:   2.698


  14 in total

Review 1.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

2.  Estrogen and progesterone attenuate glutamate neurotoxicity via regulation of EAAT3 and GLT-1 in a rat model of ischemic stroke.

Authors:  Sara Nematipour; Zeinab Vahidinia; Majid Nejati; Homayon Naderian; Cordian Beyer; Abolfazl Azami Tameh
Journal:  Iran J Basic Med Sci       Date:  2020-10       Impact factor: 2.699

Review 3.  SLC1 glutamate transporters.

Authors:  Christof Grewer; Armanda Gameiro; Thomas Rauen
Journal:  Pflugers Arch       Date:  2013-11-19       Impact factor: 3.657

4.  Developmental effect of light deprivation on synaptic plasticity of rats' hippocampus: implications for melatonin.

Authors:  Sayyed Alireza Talaei; Abolfazl Azami; Mahmoud Salami
Journal:  Iran J Basic Med Sci       Date:  2016-08       Impact factor: 2.699

5.  Estrogen agonist genistein differentially influences the cognitive and motor disorders in an ovariectomized animal model of Parkinsonism.

Authors:  Elaheh Arbabi; Gholamali Hamidi; Sayyed Alireza Talaei; Mahmoud Salami
Journal:  Iran J Basic Med Sci       Date:  2016-12       Impact factor: 2.699

6.  Astrocyte-derived tissue Transglutaminase affects fibronectin deposition, but not aggregation, during cuprizone-induced demyelination.

Authors:  Nathaly Espitia Pinzon; Berta Sanz-Morello; John J P Brevé; John G J M Bol; Benjamin Drukarch; Jan Bauer; Wia Baron; Anne-Marie van Dam
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

Review 7.  Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors.

Authors:  Md Jakaria; Shin-Young Park; Md Ezazul Haque; Govindarajan Karthivashan; In-Su Kim; Palanivel Ganesan; Dong-Kug Choi
Journal:  Front Mol Neurosci       Date:  2018-08-29       Impact factor: 5.639

8.  Temporal Changes in In Vivo Glutamate Signal during Demyelination and Remyelination in the Corpus Callosum: A Glutamate-Weighted Chemical Exchange Saturation Transfer Imaging Study.

Authors:  Do-Wan Lee; Hwon Heo; Chul-Woong Woo; Dong-Cheol Woo; Jeong-Kon Kim; Kyung-Won Kim; Dong-Hoon Lee
Journal:  Int J Mol Sci       Date:  2020-12-12       Impact factor: 5.923

9.  Dock3 protects myelin in the cuprizone model for demyelination.

Authors:  K Namekata; A Kimura; C Harada; H Yoshida; Y Matsumoto; T Harada
Journal:  Cell Death Dis       Date:  2014-08-28       Impact factor: 8.469

10.  Comparative Proteome Research in a Zebrafish Model for Vanishing White Matter Disease.

Authors:  Doeun Kim; Yu-Ri Lee; Tae-Ik Choi; Se-Hee Kim; Hoon-Chul Kang; Cheol-Hee Kim; Sangkyu Lee
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.